Abstract
Background: Optimum treatment strategies for locally advanced gastric cancer (LAGC) remain a subject of debate. This study evaluates the efficacy of various treatment modalities, focusing on the extent of lymph node dissection and adjuvant therapy.
Methods: A retrospective cohort of 350 patients was analyzed alongside a validation cohort of 3,568 patients from the SEER database. Patients were categorized into four groups: D1 dissection plus chemotherapy (D1CT), D1 plus chemoradiotherapy (D1CRT), D2 plus chemotherapy (D2CT), and D2 plus chemoradiotherapy (D2CRT). Propensity score matching (PSM) was employed to adjust for baseline confounding.
Results: D2CRT demonstrated superior overall survival (OS) and disease-free survival (DFS) compared to other groups. Notably, D1CRT achieved survival outcomes comparable to D2CT.
Conclusions: D2CRT is the most effective modality for LAGC. For patients receiving D1 dissection, adjuvant chemoradiotherapy serves as a viable salvage option.
Introduction
Locally advanced gastric cancer (LAGC) is a significant global health challenge. While surgical resection is the cornerstone of treatment, the optimal combination of lymph node dissection (D1 vs. D2) and adjuvant therapy (chemotherapy vs. chemoradiotherapy) is not universally agreed upon. D2 dissection is technically demanding, and in many real-world clinical settings, D1 dissection is more common. This study investigates whether adjuvant chemoradiotherapy can compensate for less extensive surgical dissection.
Methods
The study utilized a primary cohort of 350 patients from Wuhan University and a validation cohort of 3,568 patients from the SEER database. To mitigate selection bias inherent in retrospective data, Propensity Score Matching (PSM) was used to balance baseline characteristics such as age, gender, and tumor stage across the four treatment groups (D1CT, D1CRT, D2CT, D2CRT).
Key Results
The analysis revealed that D2 dissection combined with adjuvant chemoradiotherapy (D2CRT) yielded the best clinical outcomes. In the primary cohort after PSM, the D2CRT group achieved a mean OS of 110.7 months and a mean DFS of 95.2 months, significantly outperforming the other three modalities.
Crucially, the study found that adding radiotherapy to D1 dissection (D1CRT) resulted in survival rates similar to those of D2 dissection with chemotherapy alone (D2CT). In the validation cohort, these trends were confirmed, showing a clear survival hierarchy where D2CRT remains the superior choice.
Discussion and Conclusion
The findings suggest that D2CRT should be considered the gold standard for LAGC treatment when feasible. However, in clinical scenarios where a D2 dissection cannot be performed, adjuvant chemoradiotherapy (D1CRT) provides a critical "salvage" effect, elevating patient outcomes to levels comparable with D2CT. This offers a practical strategy for clinicians in resource-limited settings or for patients who are not candidates for extensive surgery. Future prospective trials are needed to further validate these findings and refine treatment protocols.
Summary updated